WebJun 30, 2024 · Boston Scientific has been an investor in Farapulse since 2014 and holds an equity stake of approximately 27 percent, according to a news release issued by the … WebSep 21, 2024 · Farapulse is pursuing regulatory approval in the U.S. and received FDA Breakthrough Designation for its endocardial ablation system in May 2024 – a designation intended to help patients receive more timely access to products that may provide a substantial improvement over existing therapies.
FARAPULSE™
WebOct 6, 2024 · Boston Scientific went on to make announcements it would acquire Farapulse for $295 million; Lumenis for $1.07 billion; and Devoro Medical for $269 million. The number of acquisitions should not come as a shock. In a past earnings call Mahoney noted Boston Scientific had $2.7 billion cash on hand and the company’s “top priority … WebJun 25, 2024 · Boston Scientific noted that the Farapulse acquisition will support its current electrophysiology portfolio by adding the FARAPULSE Pulsed Field Ablation (PFA) System. PFA is a non-thermal ablation system indicated to treat atrial fibrillation (AF) as well as other cardiac arrhythmias. dawn for washing a car
Nathan Hillier - Training Manager FARAPULSE Pulsed …
WebSep 25, 2024 · Boston Scientific Corporation BSX signed an investment agreement with an exclusive option to acquire Farapulse, Inc, a privately-held company developing a pulsed field ablation (“PFA”)... WebAbout. Experienced in electrophysiology and CRM and is part of the EMEA EP medical education team for Boston Scientific supporting employee … WebPulsedfield ablation (PFA) is a non-thermal ablative approach in which cell death isobtainedbyapplyinghighvoltageultra-shortpulsestoinducepores in cell membranes.11Using this technology, initial clinical studies have reported high durability of PVI and procedural safety.12Indeed, with the threshold for irreversible injury after PFA being … dawn for washing windows